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 Antiretroviral drug maraviroc is an inhibitor of CCR5-trophic HIV virus and belongs 
to the group of entry inhibitors. Nowadays, maraviroc is administered as part of combination 
antiretroviral therapy (cART) primarily in adults, children over the age of two and pregnant 
women to reduce the risk of transmission of HIV to the fetus. The knowledge of interactions 
of maraviroc with drug transporters in placenta is crucial for optimizing the therapy during 
pregnancy, both in terms of efficacy and potential adverse effects. Maraviroc is known 
substrate of ABCB1 transporter, which plays a protective role to the fetus by its efflux activity 
in the apical membrane of trophoblast. However, the results of recent study employing dually 
perfused human placenta suggest involvement of other transport mechanisms in the maraviroc 
transplacental pharmaocokinetics, especially those operating in the opposite direction to 
ABCB1. 
 The aim of this study was to evaluate in vitro studies whether, besides ABCB1, 
maraviroc interacts with other transplacentar transporters. First, an accumulation study and 
bidirectional transport of maraviroc across the monolayer of placental BeWo b30 cells was 
performed. Significant reduction in maraviroc accumulation in the presence of                 
verapamil (100 µM), ritonavir (10 µM) and elacridar (2 µM) suggests, that some influx 
transporters might be involved. On the other hand, an increase of accumulation in the 
presence of inhibitor MK-571 (50 µM) suggests also involvement of some ABCCs efflux 
transporter(s). After the following evaluation of the transport study a significant transfer of 
maraviroc in B-A direction was observed sensitive to the presence of ritonavir and MK-571. 
In order to identify the interacting transport mechanisms in vitro studies were performed 
using MDCKII cells overexpressing human ABCC1 transporter and A431 cells 
overexpressing human OATP2B1,  - 1A2 or -1B3 transporter. We revealed substrate affinity 
of maraviroc to ABCC1, OATP1A2 and OATP1B3, but not to OATP2B1. 
 Based on the obtained data we can suggest, that maraviroc interacts with several drug 
transporters in placenta that could partly reverse the effect of apically localized ABCB1. 
Considering the fact that antiretroviral therapy is always administered as combination of 
drugs in developed countries, it can be assumed that maraviroc will be susceptible to drug-
drug interactions and this newly obtained data could contribute to better understanding of the 
transplacental pharmacokinetics of maraviroc and optimization of the therapy. 
